Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
XOMA Corporation Snapshot 5
XOMA Corporation Overview 5
Key Information 5
Key Facts 6
XOMA Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
XOMA Corporation - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
XOMA Corporation - Pipeline Products Glance 13
XOMA Corporation - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
XOMA Corporation - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
XOMA Corporation - Drug Profiles 17
XOMA-213 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
XOMA-358 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Monoclonal Antibodies for Undisclosed Disease 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing’s Disease 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibodies to Antagonize Parathyroid Hormone 1 Receptor for Hyperparathyroidism and Malignancy Induced Hypercalcemia 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
XMet-A 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
XOMA-129 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
XOMA-3-BB 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Antibody to Modulate GPCR 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
XOMA Corporation - Pipeline Analysis 27
XOMA Corporation - Pipeline Products by Target 27
XOMA Corporation - Pipeline Products by Route of Administration 28
XOMA Corporation - Pipeline Products by Molecule Type 29
XOMA Corporation - Pipeline Products by Mechanism of Action 30
XOMA Corporation - Recent Pipeline Updates 31
XOMA Corporation - Dormant Projects 34
XOMA Corporation - Discontinued Pipeline Products 35
Discontinued Pipeline Product Profiles 35
gevokizumab 35
XOMA Corporation - Company Statement 36
XOMA Corporation - Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables
XOMA Corporation, Key Information 5
XOMA Corporation, Key Facts 6
XOMA Corporation - Pipeline by Indication, 2016 8
XOMA Corporation - Pipeline by Stage of Development, 2016 9
XOMA Corporation - Monotherapy Products in Pipeline, 2016 10
XOMA Corporation - Out-Licensed Products in Pipeline, 2016 11
XOMA Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 12
XOMA Corporation - Phase II, 2016 13
XOMA Corporation - Phase I, 2016 14
XOMA Corporation - Preclinical, 2016 15
XOMA Corporation - Discovery, 2016 16
XOMA Corporation - Pipeline by Target, 2016 27
XOMA Corporation - Pipeline by Route of Administration, 2016 28
XOMA Corporation - Pipeline by Molecule Type, 2016 29
XOMA Corporation - Pipeline Products by Mechanism of Action, 2016 30
XOMA Corporation - Recent Pipeline Updates, 2016 31
XOMA Corporation - Dormant Developmental Projects,2016 34
XOMA Corporation - Discontinued Pipeline Products, 2016 35
XOMA Corporation, Subsidiaries 39

List of Figures
XOMA Corporation - Pipeline by Top 10 Indication, 2016 8
XOMA Corporation - Pipeline by Stage of Development, 2016 9
XOMA Corporation - Monotherapy Products in Pipeline, 2016 10
XOMA Corporation - Out-Licensed Products in Pipeline, 2016 11
XOMA Corporation - Pipeline by Target, 2016 27
XOMA Corporation - Pipeline by Route of Administration, 2016 28
XOMA Corporation - Pipeline by Molecule Type, 2016 29
XOMA Corporation - Pipeline Products by Mechanism of Action, 2016 30